This article presents ongoing research at VIDO-InterVac for the development of safer and more effective adjuvants. These include adjuvants that stimulate innate immunity in the body and combination adjuvants.
Paul Hodgson
Advertisement
Paul Hodgson is an associate director business development at VIDO-InterVac
Articles by Paul Hodgson
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
2
Nano24's Inhaled EXO-CD24 Cuts ARDS Mortality in Phase 2b Trial
3
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
4
Akeso's Ivonescimab Enters Phase 2/3 Biliary Tract Cancer Trial in US
5